

PUBLICATIONS

- Betancourt AA, Delgado CA, Estévez ZC, Martínez JC, Ríos GV, Aureoles-Roselló SR, Zaldívar RA, Guzmán MA, Baile NF, Reyes PA, Ruano LO, Fernández AC, Lobaina-Matos Y, Fernández AD, Madrazo AI, Martínez MI, Baños ML, Alvarez NP, Baldo MD, Mestre RE, Pérez MV, Martínez ME, Escobar DA, Guanche MJ, Cáceres LM, Betancourt RS, Rando EH, Nieto GE, González VL, Rubido JC. Phase I clinical trial in healthy adults of a nasal vaccine candidate containing recombinant hepatitis B surface and core antigens. *Int J Infect Dis*; 2007;11(5):394-401. Available in: [https://www.ijidonline.com/article/S1201-9712\(06\)0192-5/fulltext](https://www.ijidonline.com/article/S1201-9712(06)0192-5/fulltext) or <https://doi.org/10.1016/j.ijid.2006.09.010>.
- Al-Mahtab M, Akbar SM, Aguilar JC, Uddin MH, Khan MS, Rahman S. Therapeutic potential of a combined hepatitis B virus surface and core antigen vaccine in patients with chronic hepatitis B. *Hepatol Int*. 2013;7(4):981-9. Available in: <https://pubmed.ncbi.nlm.nih.gov/26202028/> or doi: 10.1007/s12072-013-9486-4.
- Al Mahtab M, Akbar SMF, Aguilar JC, Guillen G, Penton E, Tuero A, Yoshida O, Hiasa Y, Onji M. Treatment of chronic hepatitis B naïve patients with a therapeutic vaccine containing HBs and HBc antigens (a randomized, open and treatment controlled phase III clinical trial). *PLoS One*. 2018;13(8):e0201236. Available in: <https://pubmed.ncbi.nlm.nih.gov/30133478/> or doi: 10.1371/journal.pone.0201236.

- Akbar SMF, Al Mahtab M, Aguilar JC, Yoshida O, Penton E, Gerardo GN, Hiasa Y. Sustained Antiviral and Liver Protection by a Nasal Therapeutic Vaccine (NASVAC, Containing Both HBsAg and HBcAg) in Patients with Chronic Hepatitis B: 2-Year Follow-Up of Phase III Clinical Trial. *Pathogens*. 2021;10(11):1440. Available in: <https://www.mdpi.com/2076-0817/10/11/1440> or doi: 10.3390/pathogens10111440.
- Akbar SMF, Al Mahtab M, Aguilar JC, Yoshida O, Khan S, Penton E, Gerardo GN, Hiasa Y. The Safety and Efficacy of a Therapeutic Vaccine for Chronic Hepatitis B: A Follow-Up Study of Phase III Clinical Trial. *Vaccines (Basel)*. 2021;10(1):45. Available in: <https://pubmed.ncbi.nlm.nih.gov/35062707/> or doi: 10.3390/vaccines10010045.
- Fernández G, L Sanchez A, Jerez E, E Anillo L, Freyre F, A Aguiar J, Leon Y, Cinza Z, A Diaz P, Figueroa N, Muzio V, G Nieto G, Lobaina Y, Aguilar A, Penton E, C Aguilar J. Five-year Follow-up of Chronic Hepatitis B Patients Immunized by Nasal Route with the Therapeutic Vaccine HeberNasvac. *EuroAsian J Hepatogastroenterol*. 2018;8(2):133-139. Available in: <https://pubmed.ncbi.nlm.nih.gov/30828555/> or doi: 10.5005/jp-journals-10018-1279.

